Inactive Instrument

pSivida Corp. Stock Nasdaq

Equities

Duration

Period

Style

PSivida : Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle	16-08-09	PU
PSivida : Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve	16-07-14	PU
PSivida : Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe	16-05-02	PU
PSivida : Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs	15-09-28	BU
PSivida : CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015	15-09-14	BU

Sector

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B